Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

ETHYL INDOLE-3-CARBOXYLATE CRS (15 MG)

ETHYL INDOLE-3-CARBOXYLATE CRS (15 MG)

776-41-0

DISCOVER
TROPISETRON IMPURITY B CRS (10 MG)

TROPISETRON IMPURITY B CRS (10 MG)

771-50-6

DISCOVER
GUAIACOL CRS (1500 MG)

GUAIACOL CRS (1500 MG)

90-05-1

DISCOVER
SODIUM LAURILSULFATE CRS (40 MG)

SODIUM LAURILSULFATE CRS (40 MG)

151-21-3

DISCOVER
TERAZOSIN HYDROCHLORIDE DIHYDRATE CRS (40 MG)

TERAZOSIN HYDROCHLORIDE DIHYDRATE CRS (40 MG)

70024-40-7

DISCOVER
Terazosin impurity A CRS, 10mg

Terazosin impurity A CRS, 10mg

23680-84-4

DISCOVER
Terazosin impurity L CRS, 10mg

Terazosin impurity L CRS, 10mg

NA

DISCOVER
TERAZOSIN IMPURITY N CRS (15 MG)

TERAZOSIN IMPURITY N CRS (15 MG)

NA

DISCOVER
KETOROLAC TROMETAMOL FOR PEAKIDENTIFICATION CRS (5 MG)

KETOROLAC TROMETAMOL FOR PEAKIDENTIFICATION CRS (5 MG)

74103-07-4

DISCOVER
ENALAPRILAT FOR SYSTEM SUITABILITY CRS (10 MG)

ENALAPRILAT FOR SYSTEM SUITABILITY CRS (10 MG)

84680-54-6

DISCOVER
PAROXETINE FOR SYSTEM SUITABILITY CRS (0.02 MG)

PAROXETINE FOR SYSTEM SUITABILITY CRS (0.02 MG)

110429-35-1

DISCOVER
NAPROXEN IMPURITY L CRS (15 MG)

NAPROXEN IMPURITY L CRS (15 MG)

3900-45-6

DISCOVER